BACKGROUND
Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...
F. Pecci, Xinan Wang, Valentina Santo et al.· Journal of Thoracic Oncology· 0 citations
Recent years have seen substantial advances in lung cancer management, with therapeutic options expanding rapidly through the integration of targeted therapies, immunotherapies, antibody-drug conjugates, and novel, immune-engaging agents. Although outcomes have improved for selected patients with non-small cell lung ca...
N. Florez, S. Patel, R. Salgia et al.· Cancer· 0 citations
A deeper understanding of the brain metastatic ecosystem may enable the development of more effective, biology-driven therapeutic approaches for NSCLC BM.
Marcel Kemper, Lea Reitnauer, A. Leonetti et al.· Cancer Biome and Targeted Th...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.